<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01356901</url>
  </required_header>
  <id_info>
    <org_study_id>AI463-232</org_study_id>
    <nct_id>NCT01356901</nct_id>
  </id_info>
  <brief_title>Persistence, Adherence and Clinical Effectiveness of Entecavir in Chronic Hepatitis B Patients</brief_title>
  <official_title>Persistence, Adherence and Clinical Effectiveness in Patients With Chronic Hepatitis B Viral Infection Treated With Entecavir in Real Life</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this observational study is to measure the real-life persistence, adherence
      and clinical effectiveness of entecavir in patients with chronic Hepatitis B viral infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sampling Method: Probability Sample (consecutive patient sampling)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Chronic hepatitis B (CHB) patients treated with Entecavir (ETV) and any switch or add-on therapy who are persistent over a time period of two years in a real-life setting.</measure>
    <time_frame>After 2 years</time_frame>
    <description>A patient will be defined as non-persistent if he misses all his doses in more than 30 subsequent days or if he fails to show up at more than one subsequent visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adherence rates using administrative measures (continuous multiple-interval medication gaps, continuous single interval medication availability), and self-report measures, 8-item self-report Morisky Medication Adherence Scale (MMAS)</measure>
    <time_frame>After 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reasons for therapy non-persistence (therapy discontinuation) and low therapy adherence (qualitative questionnaire for causal assessment of non-persistence/non-adherence)</measure>
    <time_frame>After 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with HBV DNA below the limit of detection (according to local lab standard), mean log reduction of HBV DNA from baseline, proportion of subjects with normal ALT and with e antigen (eAg)/Surface antigen (sAg) seroconversion/loss</measure>
    <time_frame>After 2 years</time_frame>
    <description>Hepatitis B virus (HBV), desoxyribonucleic acid (DNA), Alanine aminotransferase (ALT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Serious adverse drug reaction ((S)ADR)s and study discontinuations due to (S)ADRs</measure>
    <time_frame>After 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with occuring resistances based on results from resistance tests</measure>
    <time_frame>After 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Health Status (SF-12速 Health Survey)</measure>
    <time_frame>Assessment of Health Status (SF-12 Health Survey) at year 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Health Status (SF-12速 Health Survey)</measure>
    <time_frame>Assessment of Health Status (SF-12 Health Survey) at year 2</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">230</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>Treatment na誰ve and pre-treated CHB patients</arm_group_label>
    <description>subanalysis with migrant and non-migrant patients</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        CHB Patients treated by Gastroenterologists/Hepatologists
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female treatment na誰ve or pre-treated CHB patients of at least 18 years of
             age

          -  Written informed consent

        Exclusion Criteria:

          -  All relevant conditions according to Summary of product characteristics (SmPC)

          -  Human immunodeficiency virus (HIV), Hepatitis C virus (HCV) or Hepatitis D virus (HDV)
             co-infection

          -  Patients currently included in any investigational trial on CHB
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Herne</city>
        <zip>44623</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2011</study_first_submitted>
  <study_first_submitted_qc>May 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2011</study_first_posted>
  <last_update_submitted>July 3, 2015</last_update_submitted>
  <last_update_submitted_qc>July 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

